Currently available treatments for cervical dystonia call for injection of botulinum toxin about 3 to 4 times a year. Is there a chance to achieve longer-lasting effects and to prolong injection intervals? A phase 2 trial with an investigational product, daxibotulinum toxin A for injection (RT002), revealed a clinically significant mean reduction of 38% from baseline in the TWSTRS total score and of 34% in the TWSTRS severity score at week 4 across all patients.
Dr Atul Patel (Kansas City Bone & Joint Clinic, USA) presented the results of the open-label, dose-escalating phase 2 study with a low (100-240 units) and a high-dose (300-450 units) daxibotulinum toxin A group in 37 patients with moderate-to-severe isolated cervical dystonia. Safety and preliminary efficacy of daxibotulinum toxin A as well as efficacy duration were assessed. The results demonstrated improvement in signs and symptoms. Clinically meaningful reductions in TWSTRS-severity, -disability, and -pain s...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« ASPIRE: High patient and clinician satisfaction Next Article
Utility of botulinum toxin in Parkinson’s disease beyond sialorrhea »
Table of Contents: TOXINS 2019
New Versions of Botulinum Toxins
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.